RAF kinase inhibitors for the treatment of melanoma

Drugs of the Future

Volumn 36, Issue 1, 2011, Pages 63-68

  Nimmagadda, N ^a   Tawbi, H ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; B RAF KINASE; B RAF KINASE INHIBITOR; CARBOPLATIN; CHIR 265; DACARBAZINE; GSK 2118436; MITOGEN ACTIVATED PROTEIN KINASE; PACLITAXEL; RAF PROTEIN; SORAFENIB; TEMOZOLOMIDE; TEMSIROLIMUS; TIPIFARNIB; UNCLASSIFIED DRUG; VEMURAFENIB; XL 281;

ANOREXIA; BONE MARROW SUPPRESSION; CANCER GROWTH; CANCER SURVIVAL; CARDIOTOXICITY; COLORECTAL CANCER; DESQUAMATION; DIARRHEA; DRUG BIOAVAILABILITY; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENZYME INHIBITION; EVENING DOSAGE; FATIGUE; GENE MUTATION; HAND FOOT SYNDROME; HEADACHE; HEMATOLOGIC DISEASE; HUMAN; HYPERTENSION; HYPOKALEMIA; IC 50; LIVER TOXICITY; LUNG NON SMALL CELL CANCER; MELANOMA; MORNING DOSAGE; NAUSEA; NEPHROTOXICITY; NONHUMAN; OUTCOME ASSESSMENT; OVARY CARCINOMA; OVERALL SURVIVAL; PROGNOSIS; RECTUM CARCINOMA; REVIEW; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE; SYNCOPE; THYROID CANCER; THYROID CARCINOMA; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING;

EID: 84952976303     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2011.036.01.1561065     Document Type: Review

References (24)

1. Jemal, A., Siegel, R., Xu, J., Ward, E. Cancer statistics, 2010. CA Cancer J Clin 2010, 60(5): 277-300.
2. Fecher, L.A., Amaravadi, R.K., Flaherty, K.T. The MAPK pathway in melanoma. Curr Opin Oncol 2008, 20(2): 183-9.
3. Davies, H., Bignell, G.R., Cox, C. et al. Mutations of the BRAF gene in human cancer. Nature 2002, 417(6892): 949-54.
4. Wilhelm, S.M., Carter, C., Tang, L. et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004, 64(19): 7099-109.
5. Carlomagno, F., Anaganti, S., Guida, T., Salvatore, G., Troncone, G., Wilhelm, S.M., Santoro, M. BAY 43-9006 inhibition of oncogenic RET mutants. J Natl Cancer Inst 2006, 98(5): 326-34.
6. Escudier, B., Eisen, T., Stadler, W.M. et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007, 356(2): 125-34.
7. Ratain, M.J., Eisen, T., Stadler, W.M. et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2006, 24(16): 2505-12.
8. Strumberg, D., Clark, J.W., Awada, A. et al. Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: A review of four phase I trials in patients with advanced refractory solid tumors. Oncologist 2007, 12(4): 426-37.
9. th Annu Meet Am Soc Clin Oncol (ASCO) (May 30-June 3, Chicago) 2008] 2008 26(15, SuppL): Abst 9072.
10. Eisen, T., Ahmad, T., Flaherty, K.T. et al. Sorafenib in advanced melanoma: A phase II randomised discontinuation trial analysis. Br J Cancer 2006, 95(5): 581-6.
11. Hauschild, A., Agarwala, S.S., Trefzer U. et al. Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol 2009, 27(17): 2823-30.
12. th Annu Meet Am Soc Clin Oncol (ASCO) (June 4-8, Chicago) 2010] 2010, 28(15, Suppl.): Abst 8511.
13. th Annu Meet Am Soc Clin Oncol (ASCO) (June 4-8, Chicago) 2010] 2010, 28(15, SuppL): Abst 8552.
14. Amaravadi, R.K., Schuchter, L.M., McDermott, D.F. et al. Phase II trial of temozotomide and sorafenib in advanced melanoma patients with or without brain metastases. Clin Cancer Res 2009, 15(24): 7711-8.
15. th Annu Meet Am Soc Clin Oncol (ASCO) (June 4-8, Chicago) 2010] 2010, 28(15, Suppl.): Abst 8502.
16. th Annu Meet Am Soc Clin Oncol (ASCO) (May 29-June 2, Orlando) 2009] 2009, 27(15, SuppL): Abst 9000.
17. th Annu Meet Am Soc Clni Oncol (ASCO) (June 4-8, Chicago) 2010] 2010, 28(15, SuppL): Abst 8529.
18. th Annu Meet Am Soc Clin Oncol (ASCO) (June 4-8, Chicago) 2010] 2010, 28(15, Suppl.): Abst 8592.
19. th Int Cong Soc Melanoma Res (Nov 4-7, Sydney) 2010] 2010, 23(6).
20. Rubinstein, J.C., Sznol, M., Pavlick, A.C. et al. Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032. J Transi Med 2010, 8: 67.
21. th Annu Meet Am Soc Clin Oncol (ASCO) (May 29-June 2, Orlando) 2009] 2009, 27(15, SuppL): Abst 3513.
22. th Int Cong Soc Melanoma Res (Nov 4-7, Sydney) 2010] 2010, 23(6).
23. th Annu Meet Am Soc Clin Oncol (ASCO) (June 4-8, Chicago) 2010] 2010, 28(15, Suppl.): Abst 8503.
24. A study to evaluate RAF265, an oral drug administered to subjects with locally advanced or metastatic melanoma (NCT00304525). ClinicalTrials.gov Web site, January 3, 2010.